Literature DB >> 8925872

Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography.

P Abadie1, P Rioux, B Scatton, E Zarifian, L Barré, A Patat, J C Baron.   

Abstract

The central benzodiazepine receptor occupancy by zolpidem in man is unknown. The present study used positron emission tomography (PET) and [11C]flumazenil to assess in five healthy volunteers, central benzodiazepine receptor occupancy in brain regions with high receptor densities 1 h following an acute oral administration of twice the usual hypnotic dose of zolpidem (20 mg). Receptor occupancy was measured in five discrete structures (middle frontal gyrus, middle temporal gyrus, posterior occipital cortex, lateral parietal cortex, and cerebellar cortex) and in a large neocortical area as the fractional change in the [11C]flumazenil bound/free ratio for the interval 15-40 min post-administration of the radiotracer. The free-radioligand concentration was estimated from the pons, a reference structure virtually devoid of central benzodiazepine receptor. With individual pons values, mean occupancy was about 21% but with spurious inter-subject variability. With pons values averaged across the five subjects and separately for control and treated condition, the occupancy was (mean +/- S.D.) 27 +/- 11% for the whole neocortex, and ranged from 26 to 29% in the five discrete structures (P < 0.01). By showing hypnotic effect at moderate occupancies, this study directly provides evidence for the full-agonist properties of zolpidem in human.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8925872     DOI: 10.1016/0014-2999(95)00633-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Anti-Tremor Action of Subtype Selective Positive Allosteric Modulators of GABAA Receptors in a Rat Model of Essential Tremors.

Authors:  Dipak V Amrutkar; Tino Dyhring; Thomas A Jacobsen; Janus S Larsen; Karin Sandager-Nielsen
Journal:  Cerebellum       Date:  2020-04       Impact factor: 3.847

Review 2.  Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.

Authors:  K J Holm; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

3.  Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes.

Authors:  Nancy A Ator; John R Atack; Richard J Hargreaves; H Donald Burns; Gerard R Dawson
Journal:  J Pharmacol Exp Ther       Date:  2009-09-29       Impact factor: 4.030

4.  A Comparison of the α2/3/5 Selective Positive Allosteric Modulators L-838,417 and TPA023 in Preclinical Models of Inflammatory and Neuropathic Pain.

Authors:  Sarah Nickolls; Hannah Mace; Rebecca Fish; Michelle Edye; Rachel Gurrell; Magnus Ivarsson; Tom Pitcher; Sachi Tanimoto-Mori; Denise Richardson; Catherine Sweatman; Janet Nicholson; Cameron Ward; John Jinks; Christine Bell; Kimberly Young; Huw Rees; Andrew Moss; Ross Kinloch; Gordon McMurray
Journal:  Adv Pharmacol Sci       Date:  2011-11-28

5.  Characterisation of the contribution of the GABA-benzodiazepine α1 receptor subtype to [(11)C]Ro15-4513 PET images.

Authors:  James F M Myers; Lula Rosso; Ben J Watson; Sue J Wilson; Nicola J Kalk; Nicoletta Clementi; David J Brooks; David J Nutt; Federico E Turkheimer; Anne R Lingford-Hughes
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-04       Impact factor: 6.200

6.  GABAA receptor gamma 2 subunit knockdown mice have enhanced anxiety-like behavior but unaltered hypnotic response to benzodiazepines.

Authors:  Dev Chandra; Esa R Korpi; Celia P Miralles; Angel L De Blas; Gregg E Homanics
Journal:  BMC Neurosci       Date:  2005-04-25       Impact factor: 3.288

7.  GABAA receptor occupancy by subtype selective GABAAα2,3 modulators: PET studies in humans.

Authors:  Aurelija Jucaite; Zsolt Cselényi; Jaakko Lappalainen; Dennis J McCarthy; Chi-Ming Lee; Svante Nyberg; Katarina Varnäs; Per Stenkrona; Christer Halldin; Alan Cross; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2016-12-24       Impact factor: 4.530

8.  The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold.

Authors:  Anthony L Gotter; Christopher J Winrow; Joseph Brunner; Susan L Garson; Steven V Fox; Jacquelyn Binns; Charles M Harrell; Donghui Cui; Ka Lai Yee; Mark Stiteler; Joanne Stevens; Alan Savitz; Pamela L Tannenbaum; Spencer J Tye; Terrence McDonald; Leon Yao; Scott D Kuduk; Jason Uslaner; Paul J Coleman; John J Renger
Journal:  BMC Neurosci       Date:  2013-08-28       Impact factor: 3.288

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.